echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Novo Nordisk's high-dose semaglutide treatment application for diabetes is rejected by the FDA

    Novo Nordisk's high-dose semaglutide treatment application for diabetes is rejected by the FDA

    • Last Update: 2021-03-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compilenewborn

    On March 22, Novo Nordisk issued an announcement stating that the company had received a notification of rejection (RFL) from the US FDA concerning semaglutide 2.


    In this RFL, the FDA requested more information, including data related to the proposed new production site.


    On January 20 this year, Novo Nordisk submitted a label extension application to the FDA to include a new dose of 2.


    The label extension application for semaglutide 2.


    The results showed that the study reached the primary endpoint: at the 40th week of treatment, using two evaluation methods, compared with the 1.


    The SUSTAIN clinical project is evaluating weekly subcutaneous injections of semaglutide.


    Reference source:

    1.


    2.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.